Bleeding Disorders, Iron, Platelet, Bleeding
Conditions
Keywords
Iron deficiency, bleeding disorder, platelet function
Brief summary
This is a prospective, single-arm, single-center observational study evaluating the impact of intravenous (IV) iron replacement in patients with inherited bleeding disorders and iron deficiency (ferritin \<50ng/dL). Subjects will undergo baseline bleeding assessments, quality-of-life measures, and laboratory tests before receiving standard-of-care IV iron. Follow-up blood work and questionnaires will be conducted post-replacement to assess for changes
Detailed description
Iron deficiency is one of the most prevalent nutritional deficiencies globally. In particular, patients with an inherited bleeding disorder are at increased risk of iron deficiency/ iron deficiency anemia given the propensity of this patient population to bleed. The impact of iron deficiency on hemoglobin synthesis is well established as it remains the leading cause of anemia worldwide, especially among menstruating women. Studies have shown a prevalence of iron deficiency as high as 93% in Hemophilia B Carriers , and iron deficiency anemia in 75% of females with von Willebrand Disease. However, platelets are also affected by iron deficiency. The effect of iron deficiency, as described in the past, is primarily seen in platelet production, where iron deficiency anemia (IDA) leads to increased platelet production or thrombocytosis. This is achieved through increased megakaryopoietic differentiation. Nonetheless, little is known about the effect of iron deficiency on platelet function and the mechanism by which it happens. In addition to that, it is unknown whether iron deficiency in patient with an underlying bleeding disorder could mitigate worsening bleeding symptoms. Studies in mice have demonstrated that platelet function was suppressed in iron-deficient mice, with evidence of iron-dependent platelet activation promoted through calcium mobilization and αIIbβ3 activation. A recent study in women with IDA demonstrated that iron levels may affect platelet function. Flow cytometry showed that women with IDA have quiescent platelets circulating in a degranulated state, which might be refractory to hemostatic activation. That same study showed that iron repletion decreased P-selectin levels and enhanced degranulation of quiescent platelets when exposed to CRP-XL or ADP. That translated into increased adhesion to collagen. A study done in children, adolescents, and young adults highlighted that mean PFA-100 closure times were significantly longer in patients with IDA, with reduced Platelet aggregation with ADP, epinephrine, and ristocetin. That same study showed that treatment with Iron improved platelet aggregation tests and significantly decreased PFA-100. The clinical relationship between bleeding, platelet function, and iron deficiency remains poorly understood. It is hypothesized that patients with iron deficiency may experience increased bleeding, with anecdotal evidence suggesting that bleeding improves as iron levels are restored. This effect is believed to be mediated by alterations in platelet function. However, the specific cellular and molecular mechanisms underlying platelet hyporesponsiveness in iron deficiency are poorly elucidated. This would particularly impact patients with an underlying inherited bleeding disorder who are at an increased risk of blood loss. This study addresses the critical gap in understanding the bleeding phenotype in iron-deficient patients with inherited bleeding disorders. To date, no studies have comprehensively evaluated this relationship. The investigator proposes a prospective study to assess bleeding phenotypes through validated bleeding assessment scores and quality of life metrics, pre and post IV iron replacement. Additionally, the investigator will analyze platelet samples pre- and post-treatment to investigate the impact of iron replenishment on platelet function and hemostatic parameters. These findings will provide valuable insights into the interplay between iron deficiency, platelet function, and bleeding severity, advancing our understanding and management of this unique patient population.
Interventions
Participants will receive IV iron therapy as part of standard management for iron deficiency
Sponsors
Study design
Eligibility
Inclusion criteria
1. Males and Females \> 15 years of age 2. Diagnosed with an Inherited Bleeding Disorder (Von Willebrand disease, platelet disorders, factor deficiencies, or bleeding disorder of unknown cause) 3. Evidence of Iron Deficiency (Ferritin \< 50 ng/mL) 4. Receiving IV iron at Hemophilia Center of Western Pennsylvania 5. Willingness to have blood drawn 6. Willing to return to clinic 3 months post infusion for final blood draw, bleeding and quality of life assessments.
Exclusion criteria
1. Previous thrombosis, VTE History. 2. Platelet count \< 100,000 \* 109/L 3. Concomitant use of antiplatelet drugs, anticoagulants, aspirin, NSAIDs.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Menstrual Blood Loss (PBAC Score) | Baseline to 3 months post-IV iron replacement | Change in menstrual bleeding 3 months after IV iron replacement, measured using the Pictorial Blood Loss Assessment Chart (PBAC). Assessed only in menstruating female participants. PBAC: Score \<100 indicates normal menstrual blood loss; scores \>100 suggest heavy menstrual bleeding. |
| Change in Epistaxis Severity Score (ESS) | Baseline to 3 months post-IV iron replacement | Change in epistaxis severity from baseline to 3 months post-IV iron replacement, measured using the Epistaxis Severity Score (ESS), a validated clinical tool for quantifying frequency, duration, and impact of nosebleeds. Score Range: 0 to 10 Scoring Interpretation: Higher scores indicate more severe or frequent nosebleeds. A reduction in score reflects clinical improvement. |
| Change in bleeding assessment (ISTH-BAT score) | Baseline to 3 months post-IV iron replacement | Change in bleeding severity 3 months after IV iron replacement, assessed using the ISTH-BAT (International Society on Thrombosis and Haemostasis Bleeding Assessment Tool). ISTH-BAT: Score range 0-56; higher scores indicate greater bleeding severity. Safety Issue: No |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Role Limitations Due to Physical Health (SF-36) | Baseline to 3 months | Change in score from the Role Physical domain of the SF-36, which evaluates problems with work or daily activities due to physical health. Score Range: 0 to 100 Scoring Interpretation: Higher scores reflect fewer role limitations. |
| Change in Role Limitations Due to Emotional Problems (SF-36) | Baseline to 3 months | Change in the Role Emotional domain score of the SF-36, which assesses limitations in daily activities due to emotional difficulties. Score Range: 0 to 100 Scoring Interpretation: Higher scores indicate better emotional role functioning. |
| Change in the Vitality domain of the SF-36, measuring energy levels and fatigue. | Baseline to 3 months | Change in the Vitality domain of the SF-36, measuring energy levels and fatigue. Score Range: 0 to 100 Scoring Interpretation: Higher scores indicate greater energy and less fatigue. |
| Change in Pain Score (SF-36) | Baseline to 3 months | Change in the Bodily Pain domain of the SF-36, evaluating intensity of pain and its effect on daily activities. Score Range: 0 to 100 Scoring Interpretation: Higher scores indicate less pain and better pain management. |
| Change in Emotional Well-Being (SF-36) | Baseline to 3 months | Change in the Mental Health domain score of the SF-36, assessing psychological well-being, mood, and anxiety. Score Range: 0 to 100 Scoring Interpretation: Higher scores indicate better emotional well-being. |
| Change in General Health Perception (SF-36) | Baseline to 3 months | Change in the General Health domain score of the SF-36, which assesses overall health perceptions. Score Range: 0 to 100 Scoring Interpretation: Higher scores reflect better perceived general health. |
| Change in Social Functioning (SF-36) | Baseline to 3 months | Change in the Social Functioning domain score, reflecting the extent to which physical or emotional health interferes with normal social activities. Score Range: 0 to 100 Scoring Interpretation: Higher scores indicate better social functioning. |
| Change in Fatigue (FACIT-F Score) | Baseline to 3 months post-IV iron replacement | Change in fatigue levels from baseline to 3 months after IV iron replacement, as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F). Score Range: 0 to 160 Scoring Interpretation: Lower scores indicate greater fatigue; higher scores indicate improved energy and well-being. |
| Change in Physical Functioning (SF-36) | Baseline to 3 months | Change in physical functioning score on the SF-36 from baseline to 3 months post-IV iron. Score Range: 0 to 100 Scoring Interpretation: Higher scores indicate better physical functioning. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Change in Mitochondrial Reactive Oxygen Species (ROS) in Platelets | Baseline to 3 months post-IV iron replacement | Evaluate changes in mitochondrial reactive oxygen species (ROS) levels in platelet samples from baseline to 3 months post-IV iron replacement. This exploratory analysis will assess whether iron repletion alters platelet oxidative stress, potentially contributing to changes in platelet function and bleeding phenotype. |
| Change in Platelet Reactivity by Flow Cytometry | Baseline to 3 months post-IV iron replacement | Evaluate changes in platelet reactivity before and after IV iron replacement, using flow cytometry to assess surface expression of activation markers (e.g., P-selectin, activated αIIbβ3 integrin) in response to standard agonists (e.g., ADP, CRP-XL). This exploratory analysis will examine whether iron repletion restores platelet responsiveness in iron-deficient individuals with inherited bleeding disorders. |
Countries
United States